A Closer Look at Emerging PARP Inhibitors in the Treatment of Prostate Cancer: Recent Clinical Trial Data for Improved Clinical and Economic Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

Clinical Advances in the Treatment of Prostate Cancer: A Closer Look at the Role of
PARP Inhibitors is a three-part webinar series

This is Part 2 of the series focusing on emerging PARP inhibitors in the treatment of prostate cancer

This activity is an archive from the webinar held February 15, 2021

This activity is valid from March 1, 2021 to March 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Description:
Prostate cancer is the most diagnosed non-cutaneous cancer in men in the US and remains the second leading cause of cancer deaths among American men, with an estimated 174,000 new cases diagnosed in 2020. Prostate cancer deaths are typically the result of castration-resistant prostate cancer (CRPC), and most patients will eventually experience disease progression despite castration, with a median duration of response of 12–24 months. Fortunately for these patients, novel therapies have changed the treatment paradigm, as recent data has shown that newer options, including PARP inhibitors, greatly improves outcomes.

Upon completion of this activity, participants will be able to:

  • Examine current unmet clinical needs in the diagnosis and management of prostate cancer

  • Analyze recent clinical trial data on the efficacy and safety of PARP inhibitor therapies in the management of prostate cancer

  • Assess the role of emerging PARP inhibitors in the evolving prostate cancer treatment paradigm

  • Identify patients who may benefit from emerging PARP inhibitor therapies in the management of prostate cancer, including combination therapy

  • Assess how the potential roles of biomarkers and barriers to adherence play a role in long-term treatment decision making for patients with prostate cancer

     

Faculty: Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel Comprehensive Cancer Center

Disclosure:

Dr. Antonarakis has served as a consultant Amgen, Astellas, AstraZeneca, Bayer, Clovis Oncology, Dendreon, Lilly, ESSA, GlaxoSmithKline, Janssen, Medivation, Merck, and Sanofi. He has recerived grants/research funding from AstraZeneca, Bristol-Myers Squibb, Celgene, Clovis Oncology, Dendreon, Genentech, Janssen, Johnson & Johnson, Merck, Novartis, Sanofi, and Tokai. He is the co-inventer of a technology licensed to Qiagen. His presentation has been peer reviewed for any bias.
 
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue